Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

February 18, 2017
Michael J. Morris, MD

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

In a phase I/IIa clinical trial, the effects of radium-223 with docetaxel (Taxotere) versus docetaxel alone on bone biomarkers was found that the patients who received the combination regimen had a greater decline in tALP and bone formation markers bALP and P1NP.

According to Morris, these bone biomarkers are important because they are one of the most closely associated tests to survival.


x